Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Pemetrexed 500mg/m2 iv
China SXT Pharmaceuticals
NSCLC
1 trial -
Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
Placebo to match LY3537982, PEMBROLIZUMAB , PEMETREXED , CARBOPLATIN , CISPLATIN
Eli Lilly Co.
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cancer
1 trial -
Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
China SXT Pharmaceuticals
Non-small Cell Lung Cancer Stage IIIA
1 trial -
RO7435846, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, PEMETREXED, Budenofalk 3mg magensaftresistente Hartkapseln, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT D
Roche Registration Limited
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer
1 trial -
SELPERCATINIB, CARBOPLATIN , SELPERCATINIB, PEMBROLIZUMAB, CISPLATIN , PEMETREXED
Eli Lilly Co.
Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
1 trial -
TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, CISPLATIN, PEMETREXED
AstraZeneca AB
Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.
1 trial -
Zipalertinib Placebo Tablets is a film-coated tablet that does not contain the active ingredient, zipalertinib., Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Taiho Pharma Netherlands B.V.
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
1 trial -
volrustomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion
AstraZeneca AB
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
1 trial -
Placebo to Osimertinib - Film-coated tablet - 40mg / 80mg, CARBOPLATIN, TAGRISSO 80 mg film-coated tablets, CISPLATIN, PEMETREXED, PEMETREXED, TAGRISSO 40 mg film-coated tablets
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN
Genmab A/S
Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).
1 trial -
Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.
Genmab A/S
Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.
1 trial -
BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, GEMCITABINE, NIVOLUMAB, PEMETREXED, PACLITAXEL, CARBOPLATIN
CERO THERAPEUTICS HOLDINGS, INC.
Non Small Cell Lung Cancer, Interstitial Lung Disease
1 trial -
Bendatax 6 mg/ ml, TAGRISSO 80 mg film-coated tablets, CISPLATIN, CARBOPLATIN, PEMETREXED, Cisplatin 1mg/ml Concentrate for Solution for Infusion, TAGRISSO 40 mg film-coated tablets, Armisarte 25 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, PACLITAXEL
AstraZeneca AB
Unresectable Non-small Cell Lung Cancer
1 trial -
Budenofalk 3mg magensaftresistente Hartkapseln, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infu
Roche Registration Limited
Untreated Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Alunbrig 30 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, Pemetrexed Viatris 25 mg/ml, solution à diluer pour perfusion
CERO THERAPEUTICS HOLDINGS, INC.
advanced ALK-positive non-small cell lung cancer
1 trial -
CETUXIMAB , MK-1084, MK-1084, MK-1084, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN , PEMETREXED , MK-1084
Merck Sharp and Dohme
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC
1 trial -
CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, LIBTAYO 350 mg concentrate for solution for infusion.
Vita (Europe) Limited
non-small cell lung cancer (NSCLC)
1 trial -
CISPLATIN, Ipilimumab, PACLITAXEL, Nivolumab Subcutaneous, CARBOPLATIN, PEMETREXED
Bristol-Myers Squibb / Pfizer EEIG
Non-small cell lung cancer (NSCLC)
1 trial -
CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., PACLITAXEL, anti-NKG2A mAb, CARBOPLATIN, PEMETREXED DISODIUM
Bristol-Myers Squibb / Pfizer EEIG
Non-small Cell Lung Cancer
1 trial -
Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, Doce onkovis 20 mg/ ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., Pemetrexed medac 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Vinorelbin onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed medac 100 mg Pulver für ein Konzentrat zur Herst
Cancer Prevention Pharma (Ireland) Limited
Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)
1 trial -
Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion, volrustomig, Cyramza 10 mg/ml concentrate for solution for infusion
AstraZeneca AB
Solid Tumors, SQ, NSQ NSCLC
1 trial -
Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Alectinib (Alecensa), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concent
Roche Registration Limited
Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Cemiplimab and Fianlimab - 1, Placebo, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, CARBOPLATIN, CISPLATIN, Cemiplimab & Fianlimab - 2, PACLITAXEL
Pharma Mar S.A.
Resectable Non-small Cell Lung Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources